The Science Behind DeepLayer
A multi-phase dermal modulation platform engineered to carry bioactive small molecules through the Epidermis, Dermis, and Hypodermis — and into the deeper biological environments where meaningful physiological activity occurs.
4
Delivery Phases
Hypodermis+
Target Depth
Topical
Application Method
Patent-Pending
IP Status
Platform Overview
Why Transdermal Delivery?
The skin is the body's largest organ — and its most sophisticated barrier. Spanning approximately 1.8 m² in the average adult, it is engineered by evolution to keep the outside world out. For formulators and biotech developers, this presents a fundamental challenge: how do you get bioactive molecules in?
Conventional topicals address the surface. Oral delivery routes compounds through the GI tract and hepatic first-pass metabolism. Injectable administration bypasses the skin entirely — but at significant cost in patient compliance, clinical infrastructure, and regulatory burden.
DeepLayer was engineered to occupy the space between surface topicals and injectable delivery. By navigating all three major skin layers — Epidermis, Dermis, and Hypodermis — and reaching the deeper vascular plexus and tissue targets beyond, DeepLayer enables small molecule delivery to biological environments that were previously accessible only via injection.
Relative Penetration Depth — Delivery Method Comparison
* Relative comparison for illustrative purposes. Actual penetration depth varies by molecule, formulation, and application conditions.
Barrier Anatomy
Navigating the Skin's Architecture
DeepLayer is engineered to carry small molecules through all three major skin layers — Epidermis, Dermis, and Hypodermis — and into the deeper biological environments where they can exert meaningful physiological effects.
Epidermis
Composition
Outermost layer composed of keratinocytes in various stages of differentiation. The stratum corneum — the topmost sublayer — is a tightly packed matrix of dead corneocytes embedded in ceramide-rich lipids.
Barrier Challenge
Primary physical and chemical barrier. The brick-and-mortar lipid architecture of the stratum corneum excludes most molecules. Enzymatic activity and tight junction networks in deeper sublayers add further resistance.
DeepLayer Approach
Phase 1 barrier modulation agents temporarily fluidize the intercellular lipid matrix of the stratum corneum, creating transient transport channels. Lipid-compatible carriers then navigate the viable epidermis sublayers without disrupting long-term barrier integrity.
Dermis
Composition
Thick connective tissue layer rich in collagen and elastin fibers, fibroblasts, and an extensive vascular and lymphatic network. The papillary dermis interfaces with the epidermis; the reticular dermis provides structural support.
Barrier Challenge
Structural transition zone with increasing molecular size and charge selectivity. The dermal-epidermal junction presents an additional selectivity boundary. Vascular uptake at this depth enables systemic distribution.
DeepLayer Approach
Hydration dynamics expand aqueous channels at the DEJ, supporting passage of polar and charged molecules. DeepLayer is engineered to achieve dermal deposition — enabling both localized dermal activity and vascular uptake for systemic distribution.
Hypodermis
Composition
Subcutaneous fat layer composed of adipocytes, loose connective tissue, and a deep vascular plexus. Acts as an energy reservoir, thermal insulator, and mechanical cushion. Contains larger blood vessels and lymphatics.
Barrier Challenge
Lipophilic environment that can sequester hydrophobic molecules. Depth and tissue density present challenges for conventional topical delivery — this layer is typically unreachable without injection.
DeepLayer Approach
DeepLayer's multi-phase architecture is designed to carry small molecules through the hypodermis and into the deeper vascular plexus — enabling delivery to biological targets that are inaccessible to conventional topical formats.
Deep Tissue & Systemic
Composition
Deeper biological environments including muscle fascia, periosteum, and systemic circulation. These targets are the site of meaningful physiological activity for recovery, wellness, and therapeutic applications.
Barrier Challenge
Conventional topical delivery cannot reach these depths. Injectable administration is the only established route — with all its associated compliance, sterility, and clinical requirements.
DeepLayer Approach
DeepLayer's differentiated value proposition: a non-invasive, topically applied platform that supports small molecule transport to deep tissue targets — without needles, without clinical administration, and without the compliance barriers of oral delivery.
Multi-Phase Platform
Four Phases. One Integrated System.
DeepLayer does not rely on a single mechanism. Four distinct phases work in concert — each addressing a specific barrier challenge in sequence.
Barrier Modulation
Stratum Corneum Preparation
Proprietary penetration-enhancing agents temporarily and reversibly modulate the lipid architecture of the stratum corneum. By fluidizing the intercellular lipid matrix, DeepLayer creates transient pathways for molecular transport — without compromising long-term barrier integrity or inducing irritation.
Key Mechanisms
- ◆Reversible lipid bilayer fluidization
- ◆Intercellular pathway expansion
- ◆Corneocyte hydration and swelling
- ◆Barrier recovery post-application
Lipid Navigation
Intercellular Transport
Specialized lipid-compatible carrier molecules guide both hydrophilic and hydrophobic actives through the intercellular lipid matrix — the primary route of transdermal molecular transport. Carrier selection is optimized for the physicochemical properties of each target molecule.
Key Mechanisms
- ◆Lipid-compatible carrier molecule selection
- ◆Hydrophilic and hydrophobic molecule compatibility
- ◆Intercellular lipid matrix traversal
- ◆Carrier-active complex stability
Hydration Dynamics
Aqueous Channel Activation
Controlled hydration of the stratum corneum expands corneocytes and increases aqueous channel permeability — enhancing transport of polar and charged molecules that would otherwise be excluded by the lipid-dominant barrier environment. Hydration state is maintained throughout the application window.
Key Mechanisms
- ◆Corneocyte expansion via controlled hydration
- ◆Aqueous channel permeability increase
- ◆Polar molecule transport support
- ◆Sustained hydration state maintenance
Dermal Deposition
Target-Depth Delivery
The culmination of the three preceding phases — bioactive molecules are deposited into the viable epidermis and upper dermis, where vascular uptake and localized biological activity can occur. Unlike surface topicals, DeepLayer is formulated to support delivery to the depth where physiological effects are meaningful.
Key Mechanisms
- ◆Viable epidermis and upper dermis targeting
- ◆Vascular uptake gateway access
- ◆Localized biological activity support
- ◆Systemic distribution potential
Sequential Phase Activation — Application to Deposition
Barrier Modulation
Lipid Navigation
Hydration Dynamics
Dermal Deposition
Molecular Compatibility
What DeepLayer Can Deliver
The platform is optimized for small molecule bioactives across a range of physicochemical profiles — hydrophilic, hydrophobic, polar, and charged.
Hydrophobic Molecules
- —Retinoids
- —Cannabinoids
- —Fat-soluble vitamins
- —Steroids
- —Terpenes
Hydrophilic Molecules
- —Vitamin C (ascorbic acid)
- —Peptides (small)
- —Amino acids
- —Water-soluble vitamins
- —Mineral ions
Amphiphilic Molecules
- —Niacinamide
- —Coenzyme Q10
- —Alpha-lipoic acid
- —Phospholipids
- —Ceramide precursors
Platform Scope
DeepLayer is a small molecule delivery platform. It is not designed for large biologics, proteins, or nucleic acid delivery. DeepLayer is not an injectable biologic or pharmaceutical drug product. All applications are subject to applicable regulatory requirements in the relevant jurisdiction.
Intellectual Property
Proprietary & Patent-Pending
The DeepLayer multi-phase dermal modulation platform is protected by patent-pending intellectual property covering the formulation system, delivery mechanism, and application methodology.
Partners licensing DeepLayer technology gain access to a defensible, differentiated delivery platform — not a commodity ingredient or off-the-shelf penetration enhancer.
Competitive Differentiation
| Feature | Standard Topical | DeepLayer |
|---|---|---|
| Dermal penetration depth | — | ✓ |
| Multi-phase mechanism | — | ✓ |
| Hydrophilic molecule support | — | ✓ |
| Hydrophobic molecule support | Partial | ✓ |
| Non-invasive application | ✓ | ✓ |
| Barrier integrity preservation | ✓ | ✓ |
| Patent-protected IP | — | ✓ |
| Licensable platform | — | ✓ |
Ready to Partner?
License the DeepLayer Platform
Available for licensing, co-development, and white-label integration. Contact us to discuss how DeepLayer can differentiate your formulation pipeline.